By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Release: New International Survey Of Lung Cancer Oncologists Highlights Underutilization Of Personalized Treatments 4/17/2015 8:55:08 AM
Hydra Biosciences, Inc. And Boehringer Ingelheim Enter Research Collaboration Focused On Renal Diseases And Disorders 4/13/2015 8:49:37 AM
FDA Files Supplemental New Drug Application For Boehringer Ingelheim's Pradaxa (dabigatran etexilate mesylate) For The Prophylaxis Of Deep Venous Thrombosis And Pulmonary Embolism After Hip Replacement Surgery 4/6/2015 6:32:43 AM
Boehringer Ingelheim Release: Type 2 Diabetes: CHMP Recommends Empagliflozin/Metformin Hydrochloride For Approval In The European Union 3/30/2015 12:44:50 PM
Boehringer Ingelheim Release: Many Atrial Fibrillation Patients At High Risk Of Stroke Fail To Receive Guideline-Recommended Oral Anticoagulant Treatment 3/16/2015 9:50:44 AM
Breckenridge Pharmaceutical, Inc. Announces Paragraph IV ANDA Litigation With Boehringer Ingelheim For Its ANDA Dabigatran Etexilate Mesylate Capsules (Pradaxa) 3/13/2015 6:56:27 AM
Boehringer Ingelheim Submits Biologics License Application To FDA For Idarucizumab, Investigational Specific Reversal Agent For Pradaxa (Dabigatran Etexilate Mesylate) 3/2/2015 7:34:49 AM
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc. (VTAE) Release: BACE Inhibitor BI 1181181 Voluntarily Put On Temporary Clinical Hold For Safety Evaluation 2/27/2015 7:04:45 AM
Boehringer Ingelheim Puts Hold on Key Alzheimer's Drug Trial 2/27/2015 7:00:54 AM
Boehringer Ingelheim Corporation Release: New Phase 2 Data In Asthma Patients Show Tiotropium Improves Lung Function, Regardless Of Allergic Status 2/23/2015 6:45:11 AM